Apolipoproten E (apoeE) is a major genetic risk factor for the development of Alzheimer's disease, yet it tends to be understudied as a potential druggable target for the mind-robbing neurodegenerative disease. Now a research team reports that a novel apoE antagonist blocks apoE interaction with N-terminal amyloid precursor protein (APP) and reduces hallmark Alzheimer's-associated pathologies.